Federal Legislation to Aid Cannabis Bankers Advances

by Sean F. Dalton, Esq.

With 33 states having legalized either medical or adult use marijuana, federal legislators are now considering legislation to ease the current regulatory constraints placed upon banks to provide services to marijuana related businesses throughout the United States.

On March 28th, the House Financial Services Committee approved the Secure and Fair Enforcement (SAFE) Banking Act which affords financial institutions clear legal guidance in this billion dollar industry.  The bill, with 152 co-sponsors was approved 45-15 with bipartisan support and was referred to the House Judiciary Committee for further consideration.

Many legislators who voted in support of the bill felt it would improve public safety by allowing marijuana related businesses to utilize banking services and lessen the risk of armed robberies of large sums of cash. Marijuana remains illegal under federal law despite a recent poll showing 61 percent of Americans approve of legalization.[1]

The SAFE Act prohibits federal banking regulators from terminating or limiting the deposit insurance or taking any adverse action against a depository institution under the Federal Deposit Insurance Act solely because the depository institution provides or has provided financial services to a cannabis-related legitimate business or service provider.

The SAFE  Act also provides protection for ancillary businesses that operate in the cannabis sector in the United States, which means that companies that operate legitimate ancillary cannabis-related businesses including packaging, supply chain services, accessories, equipment, lightings, and grow systems would also be able to access the services of financial institutions along with professional services related to the providing of these services.

The bill requires financial institutions operating in this sector to continue following guidance provided by the Financial Crimes Enforcement Network (FinCEN) within the Department of Treasury.

It is expected that a companion bill will be introduced in the Senate in the coming weeks.

[1] General Social Survey, NORC at the University of Chicago, 2018.


CannaBusiness in South Jersey: Economic Implications and Considerations

Cooper Levenson attorney Sean F. Dalton will speak at a “Sound off for South Jersey” event, organized by the Southern New Jersey Development Council. The conference will be held on March 22 from 8 a.m. – 11 a.m. at Resorts Casino Hotel, Atlantic City, N.J.

A description of the program states “With New Jersey’s expansion of medical cannabis and adult-use legalization pending, this high-level discussion will focus on the emerging topics impacting the business community.

Register at http://snjdc.org/event/sound-off-for-south-jersey/



Brittany Bonetti Presents at 1st Annual Cannabis Law Symposium

March 13 at the New Jersey Law Center in New Brunswick

Atlantic City, N.J. — Feb. 4, 2019 – As lawmakers move closer to legalizing cannabis for personal use in New Jersey, Cooper Levenson attorney Brittany A. Bonetti weighs in on the legal landscape at the first annual Cannabis Law Symposium on Wed., March 13, 2019 in New Brunswick. Bonetti is a member of the NJSBA Cannabis Law Special Committee, which focuses on the intricacies of cannabis issues from a legal perspective.

The symposium takes place at the New Jersey Law Center, 1 Constitution Square, New Brunswick, N.J., from 9 a.m. to 4 p.m. Bonetti will present at 11:25 a.m. on physician obligations and patient protections and other healthcare practitioner and health institution concerns. Topics also will include real estate leases in the cannabis space, labor and employment laws, valuing businesses in the cannabis industry, how to minimize tax burdens, and the path to licensure.

The program is presented by NJICLE, and CLE credit is available to attendees. Cost is $235 per participant with discounted member rates for NJSBA. For more information or to register, visit https://tcms.njsba.com/PersonifyEbusiness/Default.aspx?TabID=1699&productId=31256314&utm_source=direct&utm_medium=email&utm_campaign=NJSBA.

Bonetti is an associate in the Cooper Levenson’s Healthcare, Cyber Law and Cannabis Law practice groups. She assists hospitals and health systems, medical staffs, individual physicians and physician groups in business and regulatory legal matters of all types, helping them navigate complicated healthcare regulations such as Stark, Fraud and Abuse, Anti-Kickback and state regulatory concerns. With a Master’s in Public Health concentrating in health systems and policy, Bonetti has a particular interest in the intersection of public policy and law.  She was recently named a top attorney in Health Care law for 2018 by SJ Magazine.

Bonetti resides in Haddonfield, N.J.

Cooper Levenson is a full service law firm since 1957, with 75 attorneys and New Jersey offices in Atlantic City and Cherry Hill. The firm also has offices in Bear, Del., Fort Lauderdale, Fla. and Las Vegas, Nev. For more information, visit www.cooperlevenson.com.

New Jersey Cannabis Law Update

by Jill T. Ojserkis, Esq., LL.M.

Despite approval of three cannabis bills, including adult use legalization, following a four hour hearing held before the joint session of the New Jersey Senate and Assembly Budget and Appropriation Committees on November 26, 2018, it appears unlikely that marijuana legislation will be voted upon in 2018. December 17, 2018 is the latest voting day of the legislative year and work still remains on gaining consensus on key issues in the bills including the tax rate, expungements and whether the proposed Cannabis Regulatory Commission would be a full-time commission. Work also remains in ensuring the number of votes needed for passage.

During the joint hearing, the Committees considered testimony related to three bills: S2703, the “New Jersey Cannabis Regulatory and Expungement Aid Modernization Act” which legalizes recreational cannabis, creates a Cannabis Regulatory Commission and provides a social justice component in the form of expungement relief and S10/S2426, the “Compassionate Use Medical Marijuana Act”, which revises requirements to authorize and access medical cannabis; establishes requirements for institutional caregivers; revises permit requirements for alternative treatment centers; and establishes additional legal protections for patients and caregivers. S2703 specifically provides that the regulation, taxing, control and legalization of marijuana products will be handled similarly to that of alcohol in New Jersey. A controversial component of S2703 also calls for all applicants, except for those seeking conditional or microbusiness licenses, to submit a statement that it has entered into a “labor peace agreement” with bona fide labor organizations.

During his keynote presentation before the Greater Atlantic City Chamber of Commerce held in the Atlantic City Campus of Stockton University on December 11, 2018, Hugh O’Beirne, President of the New Jersey Cannabis Industry Association, stated his belief that it is better for New Jersey to wait to get it right and to get needed buy-in rather than to rush given the potentially staggering economics. O’Beirne compared the population of Colorado with approximately 5.6 million residents to the more densely populated New Jersey, with 9 million residents. He also noted that New Jersey has far more visitors than Colorado. The New Jersey Office of Legislative Services (“OLS”), using Colorado as a model, calculated the per person annual spend on legal marijuana to be approximately $194.61. Were New Jersey to experience the same per resident sales as Colorado, the OLS estimates total retail sales of recreational marijuana in New Jersey to approximately $1.75 billion yielding aggregate tax revenue of approximately $210 million annually. Not addressed by O’Beirne or the OLS was the quickly falling price of marijuana in Colorado, which will see a marked reduction in tax revenue due to taxes being based on sales price.

In a December 11, 2018 article, NJ.com reported that 50 towns in New Jersey (or 10% of towns statewide), had banned legal marijuana businesses from operations. S2703 states that if municipalities do not “opt out” of a specific classes or all of licenses within 180 days of enaction of the law, they will be unable to do so for 5 years. The NJ.com article also noted that notwithstanding a municipality’s opt-out, the proposed bills would still permit residents over 21 to possess and use a small amount of legal marijuana in a private residence in that municipality.

S2703 also contains a combined 12% tax rate to be paid to the State and a 2% municipal excise tax. Proponents of this tax rate believe that this lower tax will promote economic growth and that, by reducing the total cost to the consumer (the price of the marijuana product plus taxes), illegal marijuana sales will be reduced. Proponents of a higher tax rate, such as Governor Murphy, believe that tax revenue should be maximized since it is the primary motivation for legalization. The New Jersey League of Municipalities has called for a 5% municipal excise tax with each licensee being required to enter into a host benefit agreement with the municipality.

The provision of licenses to microbusinesses in S2703 is seen as a means to reduce the barriers to entry by small business. Microbusinesses may have no more than 10 employees with 100% of the ownership interests being comprised of New Jersey residents who have lived in the State for at least two years. Further, and in order to promote economic opportunities within the State, at least 51% of the owners, directors, officers or employees of the microbusiness must be residents of the municipality or neighboring municipality where the microbusiness is to be located.

It has also been reported that shortly before the hearing before the joint Committees, changes were made to S10/S2426 which had offered medicinal marijuana patients broad employment protections. While the revised S10 does not permit termination of an employee merely because s/he is registered with the medical marijuana program, there are no other significant protections. Employers may maintain a drug testing policy and a prohibition against positive test results.

As written for Capaldi Reynolds & Pelosi, Certified Public Accountants newsletter

Banking and Marijuana-Related Businesses, by Michael L. Salad and Brittany A. Bonetti

Click here for a printable copy: Michael Salad and Brittany Bonetti article Banking and Marijuana-Related Businesses  NJ Lawyer mag Oct 2018

This article was originally published in the October 2018 issue of New Jersey Lawyer, a publication of the New Jersey State Bar Association, and is reprinted here with permission.

Since federal regulators began reinterpreting the United States’ position on marijuana in 2014, the number of state-sanctioned marijuana-related businesses (MRBs) has exploded, leaving MRBs with an abundance of cash, but not many places to deposit it. The New Jersey Department of Health approved six alternative treatment centers (ATCs), which pro-vide qualifying patients with medicinal marijuana and related paraphernalia. These ATCs are a type of MRB. On July 16 of this year, the department released a request for applications (RFA) for up to six additional ATCs. The department expects to release future RFAs this fall and in the winter of 2019.

This year’s forecast for nationwide sales of state-sanctioned marijuana is estimated to be $11 billion.1 However, the vast majority of the United States’ financial services industry has declined to enter the MRB market due to uncertainties in state and federal marijuana laws, rules, regulations, and policies. While it is undisputed that the mechanisms for harmonizing jurisdictional treatment of marijuana are incomplete, banks and credit unions may utilize certain tools to mitigate the risk of serving MRBs. Financial institutions seeking to serve MRBs must implement enhanced risk assessment and customer due diligence.

Examination of Federal Law

Marijuana remains classified as a Schedule I controlled substance by the federal Controlled Substances Act (CSA), and as such, manufacturing, distributing, or dispensing marijuana remains illegal at the federal level.2 The Bank Secrecy Act (BSA) requires all banks to file suspicious activities reports (SAR) for transactions conducted or attempted by, at, or through the bank and aggregating $5,000 or more, if the bank suspects, or has reason to suspect the transaction: 1) may involve potential money laundering or other illegal activity; 2) is designed to evade the BSA or its implementing regulations; or 3) has no business or apparent lawful pur-pose.3 The Money Laundering Control Act makes it a criminal offense to carry out certain monetary transactions with funds derived from specified unlawful activities, including funds derived from marijuana-related conduct.4 Regardless of whether a state has sanctioned MRBs, funds derived from MRBs trigger SAR filing obligations for banks depositing those funds.

From 1970 to 2013, federal regulators strictly construed the meaning of enforcement actions under the CSA and BSA. As such, the United States Department of the Treasury could find financial institutions to be in violation of the Money Laundering Control Act, jeopardizing such institutions’ eligibility with the Federal Deposit Insurance Corporation and participation with the Federal Reserve.

On Aug. 29, 2013, the Department of Justice released the now-defunct Cole memo issued by then Deputy Attorney General James M. Cole, which advised federal prosecutors to limit marijuana prosecutions to eight priorities. In response to the Cole memo, on Feb. 14, 2014, the Department of the Treasury, via the Financial Crimes Enforcement Network (FinCEN), clarified the obligations of financial institutions under the BSA, and instructed that:

  • A financial institution providing financial services to a marijuana-related business that it reasonably believes, based on its customer due diligence, does not implicate one of the Cole memo priorities or violate state law should file a “Marijuana Limited” SAR.
  • A financial institution filing a SAR on a marijuana-related business that it reasonably believes, based on its customer due diligence, implicates one of the Cole memo priorities or violates state law should file a “Marijuana Priority” SAR.
  • If a financial institution deems it necessary to terminate a relationship with a marijuana-related business in order to maintain an effective anti-money laundering compliance pro-gram, it should file a SAR and note in the narrative the basis for the termination. Financial institutions should use the term “Marijuana Termination” in the narrative section.

FinCEN’s Feb. 2014 guidance offers banks a way to comply with BSA obligations while engaging in financial trans-actions with state-sanctioned MRBs. Fin-CEN emphasized that banks with MRB accounts must implement enhanced due diligence procedures to identify conduct that implicates the eight Cole memo priorities. While the Cole memo was rescinded on Jan. 4 of this year, the Department of the Treasury confirmed that “The SAR reporting structure set forth in FinCEN’s Feb. 2014 guidance remains in place.”5 In effect, the eight Cole memo priorities still dictate the type of SAR that banks must file when accepting funds from MRBs. The Feb. 2014 FinCEN guidance does not, however, provide banks with immunity from civil or criminal penalties for serving MRBs. Instead, the guidance clarified the way in which banks may meet their BSA obligations while providing services to MRBs. Constant SAR filings and maintenance of an enhanced due diligence pro-gram can be a burden on banks that hold MRB accounts. It is the authors’ experience that some banks choose to hire out-side consultants to assist with the enhanced due diligence required for handling MRB accounts.

The Cole memo no longer provides banks with the level of comfort it once did; however, the Rohrabacher–Blumenauer Amendment remains in effect,6 meaning that no federal funds allocated to the Department of Justice may be used to prevent states from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana. Thus, the Rohrabacher–Blumenauer Amendment arguably shields banks serving state-sanctioned medical marijuana businesses from federal prosecution, provided those entities are compliant with state law.

Banks accepting MRB accounts must understand that the FinCEN guidance does not change the law and that the practical effect of FinCEN guidance can be limited when MRB issues arise in federal court. Federal judges have expressed reluctance to use their equitable powers to facilitate marijuana-related conduct that remains illegal under federal law.7

Examination of New Jersey Law 

New Jersey approved the issuance of the original six ATC permits through the New Jersey Compassionate Use Medical Marijuana Act in Jan. 2010.8 The act required these first six ATCs to be non-profit entities.9 The New Jersey Department of Health reports that 10,000 patients have joined the state’s medicinal marijuana program since Phil Murphy took office as governor in January of this year.10 As a result, the New Jersey Department of Health found that an additional six ATCs were necessary to meet the needs of the state’s growing patient population. Unlike the original six ATCs, the second set of ATCs may be either for-profit or nonprofit entities.11 In an effort to create more options for patients, the commissioner of the New Jersey Department of Health is encouraging physicians to view medicinal marijuana as a safe, effective method of treatment.

Even with the act and the Murphy administration’s support for New Jersey’s medicinal marijuana program, the manufacturing, distribution, and dispensing of medicinal marijuana remains illegal at the federal level. Accordingly, banks that accept ATC depository accounts, must comply with FinCEN’s SAR guidelines. While some banks in New Jersey have taken on MRB depository accounts, these same banks may be reluctant to provide MRBs with loans. As such, MRBs have heavily relied upon private financing. Some of the original six ATCs reportedly experienced financing challenges due to their nonprofit status.12 In April of this year, as a further obstacle to MRB financing, the U.S. Small Business Administration updated its standard operating procedures, which now explicitly prohibit SBA loans to businesses that directly derive revenue from marijuana-related activities (e.g., marijuana growers and marijuana dispensaries) or support the end-use of marijuana (e.g., marijuana testing services; entities providing lights, hydroponic equipment, or smoking devices; and leasing space to marijuana businesses).13 The second set of ATCs have the option of being for-profit, and, as such, will likely have better luck attracting private financing.

With regard to criminal implications at the state level, New Jersey law grants immunity from state prosecution through the act.14

Qualifying patient, primary caregiver, alternative treatment center, physician, or any other person acting in accordance with the provisions of this Act, shall not be subject to civil or administrative penalty, or denied any right or privilege, including, but not limited to, civil penalty or disciplinary action by a professional licensing board, related to the medical use of marijuana as authorized under the Act.15

Although the act does not define ‘per-son,’ New Jersey law states that the default definition of a ‘person’ includes “corporations, companies, associations, societies, firms, partnerships and joint stock companies” in the absence of a contrary definition.16  As such, the act arguably protects New Jersey financial institutions from state prosecution arising from financial transactions with ATCs.


Federal guidance and state laws have given New Jersey financial institutions a path for offering depository services to New Jersey ATCs with reduced risk. Though the current guidance may expand or contract in time, banks and credit unions, which comply with SAR filing requirements delineated by Fin-CEN and implement enhanced customer due diligence, may provide services to a highly underserved market. The need for banking will be magnified by New Jersey’s ongoing expansion of its medicinal marijuana program and the need will be further magnified if recreational marijuana use is legalized in the state.


  1. Aaron Smith, The U.S. Legal Marijuana Industry is Booming, CNN Money (Jan. 31, 2018) available at https://money.cnn.com/2018/01/31/news/marijuana-state-of-the-union/.
  2. 21 U.S.C.A. § 812.
  3. 31 C.F.R. § 1020.320(a)(2).
  4. 18 U.S.C.A. § 1956.
  5. Letter from Drew Maloney, assistant secretary for legislative affairs, Department of the Treasury, to the Hon. Denny Heck, congressman for Washington’s 10th Congressional District (Jan. 31, 2018).
  6. The federal Rohrabacher-Blumenauer Amendment provides that no federal funds, made available to the Department of Justice, may be used to prevent states from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana. This federal prohibition was initially passed in 2014 and has been intermittently renewed since then. The amendment was most recently renewed on March 23, in the Consolidated Appropriations Act, 2018 (Pub. L. 115–141), which remains in effect through Sept. 30, and will be up for renewal at that time.
  7. Fourth Corner Credit Union v. FRB, 861 F.3d 1052 (10th Cir. 2017).
  8. N.J. Stat. 24:61-1 et seq.
  9. New Jersey Compassionate Use Medical Marijuana Act provides that the Department of Health “shall seek to ensure the availability of a sufficient number of alternative treatment centers throughout the State, pursuant to need, includ-ng at least two each in the north-ern, central, and southern regions of the State. The first two centers issued a permit in each region shall be nonprofit entities, and centers subsequently issued permits may be nonprofit or for-profit entities.” N.J. Stat. § 24:6I-7(a).
  10. ew Jersey Department of Health, Medicinal Marijuana Program Grows by 10,000 Patients Since Start of Murphy Administration (July 2, 2018) available at https://www.state.nj.us/health/news/2018/approved/20180702b.shtml.
  11. New Jersey Department of Health, Division of Medicinal Marijuana, Request for Applications (July 16, 2018) available at https://nj.gov/health/medicalmarijuana/docu-ments/ATC_RFA_July2018.pdf.
  12. Susan K. Livio, N.J. Issues Permit to Second Medical Marijuana Dispensary, NJ.Com (Sept. 11, 2013, at 10:40 p.m.) https://www.nj.com/politics/index.ssf/2013/06/nj_issues _permit_to_second_med.html.
  13. SBA Policy Notice, “Revised Guidance on Credit Elsewhere and Other Provisions in SOP 50 10 5(J),” No. 5000-17057 (April 3, 2018).
  14. N.J. Stat. § 24:6I-6.
  15. Id.
  16. N.J. Stat. § 1:1-2.

MICHAEL L. SALAD is a partner with Cooper Levenson, P.A. and a member of the firm’s business and tax, cannabis law, and cyber risk management practice groups.

BRITTANY A. BONETTI is an associate with Cooper Levenson, P.A. and a member of the firm’s healthcare and cannabis law practice groups.


New Jersey Embarks on New Direction in Marijuana Cases

Signaling a change in state policy dating back over 50 years, Attorney General Gurbir Grewal authorized municipal prosecutors to consider social justice grounds as a basis for exercising discretion to amend or dismiss possessory marijuana cases.

“To the extent permitted by law, a municipal prosecutor should consider the impact of adverse collateral consequences of a conviction based on the specific circumstances or factors presented by the defendant or elicited by the court,” announced Attorney General Grewal.

Some of the factors prosecutors can consider are the age and prior record of the defendant; adverse employment or military enlistment consequences; adverse educational, housing, immigration or family consequences; as well as the nature and circumstances of the offense and the arrest.

“The guidance provided remains in effect pending the New Jersey legislature’s consideration of  legalizing recreational marijuana this Fall,” noted Sean F. Dalton, Esquire of the Cooper Levenson law firm. “If possessory amounts of marijuana is legalized, the next question is whether the legislature will fast track the expungement of criminal records for those convicted prior to the effective date of this new law.”

The New Jersey Attorney General’s decision is not binding on federal law enforcement officials which still categorizes marijuana as a Schedule 1 illegal drug under federal law.

NJ Attorney General Decision Marks Transition in NJ Marijuana Policy

by: Sean F. Dalton, Esquire

Last week, New Jersey’s chief law enforcement officer signaled a positive step in efforts to curb marijuana prosecution in New Jersey.  On July 24, 2018, Attorney General Gurbir Grewal  instructed municipal prosecutors in New Jersey’s 565 municipalities to postpone prosecution of all marijuana-related offenses until early September pending review of recommendations from a Marijuana Taskforce formed by Attorney General Grewal. On the same day, Glenn A. Grant, Acting Administrative Director of New Jersey Courts, notified municipal judges to give “due consideration” to adjournment requests by prosecutors.

The Marijuana Taskforce, consisting of prosecutors, defense attorneys, police, and civil rights organizations will review the scope and appropriate use of discretion in marijuana-related offenses in municipal court by municipal prosecutors.  Currently, NJ Municipal Court Guidelines   prohibit municipal prosecutors from plea bargaining or downgrading drug offenses including marijuana possession cases. The Taskforce will likely recommend a relaxation of the Guidelines as it relates to marijuana-related charges.

According to 2016 FBI Crime Data, New Jersey had the second highest marijuana arrest rate in the United States.   In addition to marijuana possession, drug paraphernalia, being under the influence of CDS, CDS in a motor vehicle and loitering for the purpose of obtaining CDS are among the thousands of marijuana-related offenses handled in New Jersey municipal courts each year.

Following the submission of the Taskforce recommendations, Attorney General Grewal will issue a directive in September providing additional guidance to prosecutors handling possessory marijuana cases which are the subject of several bills in New Jersey.  The Attorney General’s action builds momentum towards the Legislature’s expected consideration of recreational marijuana legalization this Fall.

Current New Jersey legislation (Senate Bill 2702, Senate Bill 2703, Assembly Bill 3819) legalizing marijuana provides for the immediate decriminalization of possessory amounts of marijuana upon passage with legalization coinciding with the commencement of marijuana sales.

The New Jersey Attorney General’s decision is not binding on federal law enforcement officials which still categorizes marijuana as a Schedule 1 illegal drug under federal law.


Jill Ojserkis quoted in ROI-NJ article today: N.J. doubling number of medical marijuana dispensaries, to 12

“Today’s announcement … has changed the entire playing field in New Jersey,” Cooper Levenson Partner Jill Ojserkis said. “Current law requires the first two of each ATC (alternative treatment center) in a region to be nonprofit. Each region currently has two nonprofits.

“The new RFA permits applicants to be either nonprofit or for-profit. It also specifically permits joint ventures and prohibits existing ATCs from participating. As a result, this announcement will likely result in a change in the landscape with existing marijuana businesses and Big Business vying for a coveted ATC permit.”

And Ojserkis believes all six will likely be for-profits, setting them up for a stronger entry into the recreational market when and if it is legalized in New Jersey.

“Banks have traditionally been reluctant to finance marijuana businesses and New Jersey ATCs have had to rely upon private financing,” she said. “I believe that most, if not all, applicants for the next six centers will be for-profit and, as such, have an easier time attracting capital and private financing.

Read entire article here: http://www.roi-nj.com/2018/07/16/healthcare/n-j-doubling-number-of-medical-marijuana-dispensaries-to-12/

A Synopsis of Significant Cannabis Bills for the current New Jersey Legislative Session

The first three bullet points pertain to recreational use. Please note this is not an exhaustive list.

  • S2703 – “New Jersey Marijuana Legalization Act”; legalizes possession and personal use of marijuana for persons age 21 and over; creates Division of Marijuana Enforcement and licensing structure; introduced on June 7, 2018 by Senators Scutari and Sweeney and referred to Senate Judiciary Committee http://www.njleg.state.nj.us/2018/Bills/S3000/2703_I1.PDF
  • S2702 – Legalizes possession and personal use of marijuana for persons age 21 and over; creates Division of Marijuana Enforcement and licensing structure; revises requirements for medical marijuana program; introduced on June 7, 2018 by Senators Scutari and Sweeney and referred to Senate Judiciary Committee  http://www.njleg.state.nj.us/2018/Bills/S3000/2702_I1.PDF
  • A3819 – Legalizes possession and personal use of small amounts of marijuana for persons age 21 and over; creates Division of Marijuana Enforcement and licensing structure; introduced on April 12,2018  by Assembly members Holley, McKnight, and Timberlake, and referred to Assembly Oversight, Reform and Federal Relations Committee http://www.njleg.state.nj.us/2018/Bills/A4000/3819_I1.PDF
  • S10 – Revises requirements to authorize and access medical marijuana; establishes requirements for institutional caregivers; revises permit requirements for alternative treatment centers; and establishes additional legal protections for patients and caregivers; introduced on May 12, 2018 by Senators Vitale, Scutari, and O’Scanlon, and referred to Senate Health, Human Services and Senior Citizens Committee http://www.njleg.state.nj.us/2018/Bills/S0500/10_I1.PDF
  • S1847 – exempts from sales and use tax sales of medical marijuana; introduced by Senator Turner on February 15, 2018 and referred to Senate Health, Human Services and Senior Citizens Committee; on March 28, 2018 reviewed by the Sales Tax Review Commission recommended to enact; http://www.njleg.state.nj.us/2018/Bills/S2000/1847_I1.PDF
  • A4097 – Provides for workers’ compensation reimbursement for medical marijuana; introduced on June 4, 2018 by Assembly member Downey and referred to Assembly Labor Committee; http://www.njleg.state.nj.us/2018/Bills/A4500/4097_I1.PDF
  • A3828 – Revises and expands list of debilitating medical conditions for medical marijuana program to include new qualifying conditions and remove restrictions on certain current conditions; introduced on April 12, 2018 by Assembly members Jasey, McKeon, and Timberlake and referred to Assembly Health and Senior Services Committee; http://www.njleg.state.nj.us/2018/Bills/A4000/3828_I1.PDF
  • A4015 – Authorizes medical marijuana for treatment of substance use disorder, authorizes all patients to be dispensed medical marijuana in edible form; introduced on May 24, 2018 by Assembly member Rooney and referred to Assembly Health and Senior Services Committee; http://www.njleg.state.nj.us/2018/Bills/A4500/4015_I1.PDF
  • A3740/AA3437 introduced on March 22, 2018 by Assembly members Conaway, Gusciora, Eustace, and Murphy, and referred to Assembly Health and Senior Services Committee; on March 22, 2018 reported as an Assembly Committee Substitute and Referred to Assembly Appropriations Committee; AHE  Voting 3/22/2018  –  r/ACS  –  Yes {6}  No {2}  Not Voting {3}  Abstains {2} http://www.njleg.state.nj.us/2018/Bills/A4000/3740_I1.PDF
  • A4235 – Establishes requirements for home delivery of medical marijuana; introduced on June 25, 2018 by Assembly members Jainieri Huttle and Downey, and referred to Assembly Health and Senior Services Committee; http://www.njleg.state.nj.us/2018/Bills/A4500/4235_I1.PDF
  • A2454 – Requires registered qualifying patient’s authorized use of medical marijuana to be considered equivalent to use of any other prescribed medication; introduced on February 1, 2018 by Assembly member Quijano and referred to Assembly Health and Senior Services Committee;
  • A3621– provides gross income tax and corporation business tax credits for qualified business expenses incurred by business that cultivates marijuana located in UEZ; introduced on March 12, 2018 by Assembly members Quijano and Wimberly and referred to Assembly Commerce and Economic Development Committee; http://www.njleg.state.nj.us/2018/Bills/A4000/3621_I1.PDF
  • A1838 – Establishes protection from adverse employment action for authorized medical marijuana patients; introduced on January 9, 2018 by Assembly members Lampitt and Gusciora and referred to Assembly Health and Senior Services Committee http://www.njleg.state.nj.us/2018/Bills/A2000/1838_I1.PDF
  • A3421 – “Jake Honig’s Law”; removes limits on amount of medical marijuana that may be dispensed at one time and expands access to edible forms, including oils; introduced on February 15, 2018 by Assembly members Conaway, Downey, Houghtaling, Gusciora, Eustace, Murphy, Holley, Vaninieri Huttle, Jasey, and referred to Assembly Health and Senior Services Committee; on April 5, 2018 trasnferred to Assembly Appropriations Committee and Reorted from Assembly Comm. As Substitute, 2nd Reading; Committee voting AAP  4/5/2018  –  r/ACS  –  Yes {11}  No {0}  Not Voting {0}  Abstains {0} http://www.njleg.state.nj.us/2018/Bills/A3500/3421_U1.PDF

“The Future of Cannabis in New Jersey”

The New Jersey Cannabis Industry Association and Cooper Levenson, Attorneys at Law produced a seminar, “The Future of Cannabis in New Jersey,” at the New Jersey Law Center, New Brunswick on March 20, 2018.

Discussions included medical expansion, patient access, decriminalization, legalization,  minority inclusion, industry and community strategies, municipal benefits, constituent engagement, workable approaches to zoning and land use, and the legal and law enforcement issues likely to face local governments as adult-use cannabis policy is adopted.

“With the support of Governor Murphy and Senate President Sweeney, the legalization of recreational marijuana appears to be not far off. Symposiums like this one are crucial to understanding the business and safety concerns,” said Lloyd D. Levenson, Esq., Chief Executive Officer, Cooper Levenson, Attorneys at Law.

Panelists, from left to right: Armen Yemenidjian, Essence Cannabis Dispensaries and Desert Grown Farms; Jaitegh Singh, Green Garden Advisors; Julie Winter, CBD for Life; Beth Stavola, CGX Life Sciences and Stavola Medical Marijuana Holdings; Leo Bridgewater, New Jersey Cannabis Commission; Kris Krane, 4Front Ventures; Shanita Penny, Minority Cannabis Industry Association; Hugh O’Beirne, New Jersey Cannabis Industry Association; and Lloyd D. Levenson, Esq., Cooper Levenson, Attorneys at Law.